Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S2352-3026(20)30205-2 http://scihub22266oqcxt.onion/10.1016/S2352-3026(20)30205-2 32563283!7302757!32563283     free     free     free       Lancet+Haematol 2020 ; 7 (8): e601-e612 Nephropedia Template TP {{tp|p=32563283|t=2020. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts |pdf=|usr=}}{{32563283}} gab.com Text Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts JO: Lancet Haematol http://www.kidney.de/pget.php?&tw=1&pmid=32563283 #FOAvip The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts. Twit Text FOAVip Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts ????Lancet Haematol http://www.kidney.de/pget.php?&tw=1&pmid=32563283 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32563283 #FOAvip English Wikipedia <ref>{{Cite pmid|32563283}}</ref> Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts #MMPMID32563283 Zeidan AM; Boddu PC; Patnaik MM; Bewersdorf JP; Stahl M; Rampal RK; Shallis R; Steensma DP; Savona MR; Sekeres MA; Roboz GJ; DeAngelo DJ; Schuh AC; Padron E; Zeidner JF; Walter RB; Onida F; Fathi A; DeZern A; Hobbs G; Stein EM; Vyas P; Wei AH; Bowen DT; Montesinos P; Griffiths EA; Verma AK; Keyzner A; Bar-Natan M; Navada SC; Kremyanskaya M; Goldberg AD; Al-Kali A; Heaney ML; Nazha A; Salman H; Luger S; Pratz KW; Konig H; Komrokji R; Deininger M; Cirici BX; Bhatt VR; Silverman LR; Erba HP; Fenaux P; Platzbecker U; Santini V; Wang ES; Tallman MS; Stone RM; Mascarenhas J Lancet Haematol 2020[Aug]; 7 (8): e601-e612 PMID32563283show ga The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts. |Adult[MESH] |Betacoronavirus/*pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/transmission/virology[MESH] |Disease Management[MESH] |Expert Testimony[MESH] |Humans[MESH] |Infection Control/*standards[MESH] |Leukemia/*therapy/virology[MESH] |Myeloproliferative Disorders/*therapy/virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/transmission/virology[MESH] |Practice Guidelines as Topic/*standards[MESH] |Resource Allocation[MESH]Special considerations in the management of adult patients with acute (epmc).pdf DeepDyve Pubget Overpricing